Q-Med's Durolane Knee Therapy Not Approvable, Needs New Trial - FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Q-Med's Durolane hyaluronic acid treatment for knee osteoarthritis needs a new randomized trial prior to FDA approval, according to the agency's Orthopedic and Rehabilitation Devices Panel
You may also be interested in...
FDA Panel Endorses Genzyme’s Synvisc-One Knee Therapy
FDA's Orthopedic and Rehabilitation Devices advisory panel voted unanimously last week to recommend approval of Genzyme's PMA supplement for a single-dose version of its hyaluronic acid-based osteoarthritis knee therapy
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.